<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156088</url>
  </required_header>
  <id_info>
    <org_study_id>IRB000087517</org_study_id>
    <nct_id>NCT03156088</nct_id>
  </id_info>
  <brief_title>Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder</brief_title>
  <official_title>Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Patients With Overactive Bladder: A Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overactive bladder syndrome (OAB) is a prevalent disorder that affects about 10% of the adult&#xD;
      population and &gt; 40% of elderly. It is defined by the presence of urgency, with or without&#xD;
      urge incontinence, in the absence of infection or other pathology. In 1997 through 1999,&#xD;
      sacral nerve stimulation SNS (InterStim, Medtronic Inc., Minneapolis, Minnesota) was approved&#xD;
      by the U.S. Food and Drug Administration (FDA) for treating urge urinary incontinence,&#xD;
      urinary urgency, and frequency. Despite the large numbers of SNS performed, the only&#xD;
      objective clinical evaluation of OAB is urodynamic detrusor instability (UDI) with some&#xD;
      evidence suggesting a correlation with outcomes after sacral neuromodulation.&#xD;
&#xD;
      Interestingly, the mechanism of action of SNS is not fully understood. Theories include&#xD;
      direct activation of efferent fibers to the striated urethral sphincter causing reflex&#xD;
      relaxation of the detrusor or potential activation of afferent fibers selectively which can&#xD;
      lead to inhibition at spinal and supraspinal levels. Somatic sacral afferent inflow&#xD;
      activation at sacral level affects the storage and emptying reflexes in the bladder and&#xD;
      central nervous system, explaining the beneficial effects of neuromodulation on both storage&#xD;
      and emptying functions of the bladder. Malaguti and his colleagues detected somatosensory&#xD;
      evoked potentials during sacral neuromodulation, revealing that sacral neuromodulation works&#xD;
      by both sacral afferent activity and somatosensory cortex activation. As sacral&#xD;
      neuromodulation is clinically proven for both storage and emptying bladder dysfunctions, it&#xD;
      is difficult to isolate its action to either sacral afferent or efferent circuits in the&#xD;
      micturition reflex pathway. In our study, we are going to study sacral neuromodulation&#xD;
      outcome predictors from the clinical and urodynamic perspectives in order to help identifying&#xD;
      the right candidates for sacral neuromodulation procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.0 Introduction: Overactive bladder syndrome (OAB) is a prevalent disorder that affects&#xD;
      about 10% of the adult population and &gt; 40% of elderly. It is defined by the presence of&#xD;
      urgency, with or without urge incontinence, in the absence of infection or other pathology.&#xD;
      In 1997 through 1999, sacral nerve stimulation SNS (InterStim, Medtronic Inc., Minneapolis,&#xD;
      Minnesota) was approved by the U.S. Food and Drug Administration (FDA) for treating urge&#xD;
      urinary incontinence, urinary urgency, and frequency. Despite the large numbers of SNS&#xD;
      performed, the only objective clinical evaluation of OAB is urodynamic detrusor instability&#xD;
      (UDI) with some evidence suggesting a correlation with outcomes after sacral neuromodulation.&#xD;
&#xD;
      Interestingly, the mechanism of action of SNS is not fully understood. Theories include&#xD;
      direct activation of efferent fibers to the striated urethral sphincter causing reflex&#xD;
      relaxation of the detrusor or potential activation of afferent fibers selectively which can&#xD;
      lead to inhibition at spinal and supraspinal levels. Somatic sacral afferent inflow&#xD;
      activation at sacral level affects the storage and emptying reflexes in the bladder and&#xD;
      central nervous system, explaining the beneficial effects of neuromodulation on both storage&#xD;
      and emptying functions of the bladder. Malaguti and his colleagues detected somatosensory&#xD;
      evoked potentials during sacral neuromodulation, revealing that sacral neuromodulation works&#xD;
      by both sacral afferent activity and somatosensory cortex activation. As sacral&#xD;
      neuromodulation is clinically proven for both storage and emptying bladder dysfunctions, it&#xD;
      is difficult to isolate its action to either sacral afferent or efferent circuits in the&#xD;
      micturition reflex pathway. In our study, we are going to study sacral neuromodulation&#xD;
      outcome predictors from the clinical and urodynamic perspectives in order to help identifying&#xD;
      the right candidates for sacral neuromodulation procedure.&#xD;
&#xD;
      2.0 Specific Aims:&#xD;
&#xD;
        -  Specific aim#1: Using the medical reporting systems, we will identify all patients who,&#xD;
           underwent sacral neuromodulation at University Hospitals of Cleveland from January 1,&#xD;
           2012 through February, 2017.&#xD;
&#xD;
        -  Specific aim#2: Reporting on the efficacy outcomes including: rate of successful&#xD;
           placement, rate of reported patient improvement after peripheral nerve (PNE) stage 1 and&#xD;
           stage 2 procedure. The proportion of patients who undergo stage 2 compared to patients&#xD;
           who had PNE. Rate of removal after full implantation and rate of battery change.&#xD;
           Finally, will report on patient satisfaction, change in disease-specific severity scores&#xD;
           and change in health-related quality of life&#xD;
&#xD;
        -  Specific aim #3: Will identify preoperative clinical and urodynamic factors that can&#xD;
           predict successful outcome and or/ failure.&#xD;
&#xD;
        -  Specific aim #4: to identify predictors in subgroups of patients with OAB including:&#xD;
&#xD;
             1. Wet versus dry subgroups.&#xD;
&#xD;
             2. With urodynamic detrusor instability (UDI) versus no UDI subgroups.&#xD;
&#xD;
             3. Neurogenic versus non-neurogenic.&#xD;
&#xD;
             4. Staged versus non-staged procedure.&#xD;
&#xD;
        -  Specific aim #5: Validating the identified predictors in a different established set of&#xD;
           patients from Cleveland Clinic.&#xD;
&#xD;
        -  Specific aim#6: Reporting on safety outcomes including intraoperative complications,&#xD;
           early postoperative complications (within 30 days) and later postoperative&#xD;
           complications. A modified Dindo classification will be utilized.&#xD;
&#xD;
      3.0 Data management and analysis: Data collection: Data will be collected from the medical&#xD;
      reporting systems (Ambulatory medical reporting system and physician portal), University&#xD;
      Hospitals Cleveland Medical Center and affiliated Hospitals, Cleveland, OH.&#xD;
&#xD;
      Data storage: REDCap software will be used for data storage. Computer software: SPSS 24 will&#xD;
      be used for statistical analysis. Statistical tests: Continuous characteristics will be&#xD;
      summarized with mean, median, and range; categorical characteristics will be summarized with&#xD;
      number and percentage. For specific aim#2 and #3, #4, #5: associations of baseline&#xD;
      characteristics with outcomes will be further evaluated using univariate, and multivariate&#xD;
      logistic regression models and summarized with odds ratios (ORs) and 95% confidence intervals&#xD;
      (CIs). Model calibration will be evaluated using the Hosmer and Lemeshow goodness-of-fit test&#xD;
      to identify the best model. The comparison will be performed using independent sample T -test&#xD;
      for normally disturbed continuous variables and Wilcoxon test for skewed data. Chi-square&#xD;
      tests will be used for comparing categorical variables. For specific aim#6, Cox proportional&#xD;
      hazard models will be used to evaluate the predictors of failure after device implantation,&#xD;
      we will be using Hosmer and Lemeshow goodness-of-fit test. All tests will be 2 sided; P&#xD;
      values less than .05 were considered statistically significant. Statistical analyses will be&#xD;
      performed using SAS software (SAS Institute, Inc, Cary, North Carolina).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Anticipated">September 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Successful treatment</measure>
    <time_frame>12 months</time_frame>
    <description>will be denoted by patient symptoms improvement and stage II InterStim. &gt; 50 improvement of patient symptoms will be considered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>if the patient has persistence of his/her symptoms, mild improvement, operation site pain or any other causes- which lead to device removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Early &lt; month and late &gt; 1 month and up to 12 months</time_frame>
    <description>Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNM efficacy in those with prior Botox bladder injection</measure>
    <time_frame>12 months</time_frame>
    <description>Success vs failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends of failure and success in neurogenic versus non-neurogenic overactive bladder</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends of failure and success in in wet versus dry patients</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends of failure and success in staged versus non-staged procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence &quot;Change&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and predictors of reoperation after SNM</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence and prediction</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Overactive Bladder Patients</arm_group_label>
    <description>Overactive bladder patients treated with sacral neuromodulator &quot;InterStim&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sacral Neuromodulator &quot;InterStim&quot;</intervention_name>
    <arm_group_label>Overactive Bladder Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Under an approved institutional review board #01-16-48, the medical and surgical database&#xD;
        will be used to identify all patients who had test stimulation, stage I and stage II sacral&#xD;
        neuromodulation at University Hospitals, Cleveland between January 1 2012 through February&#xD;
        2017. The study protocol is designed in accordance with the Strengthening the Reporting of&#xD;
        Observational Studies in Epidemiology (STROBE) statement&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant adult female at least 18 years old.&#xD;
&#xD;
          -  Persistent symptoms in spite of the use of at least two anticholinergics&#xD;
&#xD;
          -  Urodynamic assessment within the previous year prior to the procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PVR &gt;150 ml on 2 occasions within 6 months prior to the procedure.&#xD;
&#xD;
          -  Surgically altered detrusor muscle, such as augmentation cystoplasty.&#xD;
&#xD;
          -  Serum creatinine level greater than twice the upper limit of normal within the&#xD;
             previous year prior to the procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. Epub 2006 Oct 2.</citation>
    <PMID>17049716</PMID>
  </results_reference>
  <results_reference>
    <citation>Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003 Jan;61(1):37-49. Review.</citation>
    <PMID>12559262</PMID>
  </results_reference>
  <results_reference>
    <citation>Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, Khullar V, Versi E. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005 Feb;95(3):335-40. Review. Erratum in: BJU Int. 2005 Apr;95(6):924.</citation>
    <PMID>15679789</PMID>
  </results_reference>
  <results_reference>
    <citation>Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006 Jan;175(1):191-4; discussion 194-5.</citation>
    <PMID>16406907</PMID>
  </results_reference>
  <results_reference>
    <citation>Malaguti S, Spinelli M, Giardiello G, Lazzeri M, Van Den Hombergh U. Neurophysiological evidence may predict the outcome of sacral neuromodulation. J Urol. 2003 Dec;170(6 Pt 1):2323-6.</citation>
    <PMID>14634406</PMID>
  </results_reference>
  <results_reference>
    <citation>von Elm E, Altman DG, Egger M, Pocock SJ, GÃ¸tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453-7.</citation>
    <PMID>18064739</PMID>
  </results_reference>
  <results_reference>
    <citation>Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005 Feb;32(1):11-8. Review.</citation>
    <PMID>15698871</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 13, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amr AbdAllah AbdelMaboud Mohamed Mahran</investigator_full_name>
    <investigator_title>Assistant lecturer of Urology</investigator_title>
  </responsible_party>
  <keyword>Predictors</keyword>
  <keyword>Sacral neuromodulation</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Overactive bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

